Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.

Original title: “ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting”

Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.

Original title: “Recordati fields $12.4B go-private offer”

The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan.

Original title: “Gilead inks $140M API supply deal, tightening ties to Korean manufacturer”

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu vaccine application will now go before the FDA’s Vaccine advisory committee.

Original title: “Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm”

Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn’t mean the industry is back from the brink. BioSpace gathered three early-stage biotech CEOs and members of the NextGen Class of 2026 to talk about surviving and thriving in this rollercoaster market, all while bringing forward the next generation of medicines.

Original title: “How To Shine As Biotech Comes Back From the Brink”

By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.

Original title: “Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug”

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

Original title: “In Alzheimer’s, Bristol Myers sees big promise beyond amyloid”

In September last year, a group of concerned stockholders raised alarm about Vaxart’s proposed reverse stock split, which the biotech was pushing for despite strong opposition from shareholders.

Original title: “Vaxart seeks shareholder support as battle over stock split brews”

A trifecta of newly inked tech partnerships—from Eli Lilly, Bristol Myers Squibb and Incyte—exemplify the increasingly central role that AI is playing in drug development.

Original title: “Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling”

In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They explore Germany’s biotech and life sciences ecosystem, including the science, infrastructure and policy changes needed to help European companies scale globally while staying rooted in Europe.

Original title: “Inside Germany’s biotech capital infrastructure and innovation engine”